Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
17.24
+0.42 (2.50%)
At close: Jul 24, 2026, 4:00 PM EDT
17.02
-0.22 (-1.25%)
After-hours: Jul 24, 2026, 7:34 PM EDT
Takeda Pharmaceutical Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 595,054 | 385,113 | 457,800 | 533,530 | 849,695 |
Short-Term Investments | 41,888 | 20,476 | 15,089 | 20,174 | 25,305 |
Cash & Short-Term Investments | 636,942 | 405,589 | 472,889 | 553,704 | 875,000 |
Cash Growth | 57.04% | -14.23% | -14.59% | -36.72% | 7.99% |
Accounts Receivable | 844,312 | 709,465 | 668,403 | 649,429 | 696,644 |
Other Receivables | 32,036 | 15,789 | 29,207 | 32,264 | 27,733 |
Total Trade Receivables | 876,348 | 725,254 | 697,610 | 681,693 | 724,377 |
Inventory | 1,396,620 | 1,217,349 | 1,209,869 | 986,457 | 853,167 |
Other Current Assets | 180,593 | 173,000 | 178,212 | 176,103 | 141,099 |
Total Current Assets | 3,090,503 | 2,521,192 | 2,558,580 | 2,397,956 | 2,593,642 |
Net Property, Plant & Equipment | 2,120,639 | 1,968,209 | 1,989,777 | 1,691,229 | 1,582,800 |
Other Intangible Assets | 3,419,348 | 3,631,560 | 4,274,682 | 4,269,657 | 3,818,544 |
Goodwill | 5,809,010 | 5,324,430 | 5,410,067 | 4,790,723 | 4,407,749 |
Long-Term Investments | 448,737 | 361,926 | 430,608 | 378,857 | 330,133 |
Other Long-Term Assets | 623,270 | 441,027 | 445,079 | 429,328 | 445,150 |
Total Assets | 15,511,506 | 14,248,344 | 15,108,792 | 13,957,750 | 13,178,018 |
Accounts Payable | 491,345 | 475,541 | 547,521 | 649,233 | 516,297 |
Current Portion of Long-Term Debt | 512,157 | 548,939 | 367,251 | 339,600 | 203,993 |
Other Current Liabilities | 1,828,571 | 1,482,040 | 1,398,331 | 1,493,107 | 1,425,440 |
Total Current Liabilities | 2,832,074 | 2,506,521 | 2,313,103 | 2,481,940 | 2,145,730 |
Long-Term Debt | 4,369,681 | 3,966,326 | 4,476,501 | 4,042,741 | 4,141,418 |
Other Long-Term Liabilities | 879,103 | 839,518 | 1,045,184 | 1,078,399 | 1,207,348 |
Total Long-Term Liabilities | 5,248,784 | 4,805,844 | 5,521,684 | 5,121,138 | 5,348,764 |
Total Liabilities | 8,080,858 | 7,312,365 | 7,834,788 | 7,603,078 | 7,494,495 |
Common Stock | 1,695,277 | 1,694,685 | 1,676,596 | 1,676,345 | 1,676,263 |
Treasury Stock | -49,128 | -74,815 | -51,259 | -100,317 | -116,007 |
Additional Paid-in Capital | 1,776,352 | 1,775,713 | 1,747,414 | 1,728,830 | 1,708,873 |
Accumulated Other Comprehensive Income | 3,294,559 | 2,351,915 | 2,509,310 | 1,508,119 | 934,173 |
Retained Earnings | 712,381 | 1,187,586 | 1,391,203 | 1,541,146 | 1,479,716 |
Total Common Shareholders' Equity | 7,429,441 | 6,935,084 | 7,273,264 | 6,354,122 | 5,683,019 |
Minority Interest | 1,208 | 895 | 741 | 549 | 504 |
Shareholders' Equity | 7,430,649 | 6,935,979 | 7,274,005 | 6,354,672 | 5,683,523 |
Total Liabilities & Equity | 15,511,506 | 14,248,344 | 15,108,792 | 13,957,750 | 13,178,018 |
Total Debt | 4,881,838 | 4,515,265 | 4,843,752 | 4,382,341 | 4,345,411 |
Net Cash (Debt) | -4,244,896 | -4,109,676 | -4,370,863 | -3,828,637 | -3,470,411 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -1347.53 | -1280.02 | -1382.88 | -1219.41 | -1100.20 |
Book Value | 7,429,441 | 6,935,084 | 7,273,264 | 6,354,122 | 5,683,019 |
Book Value Per Share | 2358.46 | 2160.03 | 2301.17 | 2023.77 | 1801.65 |
Tangible Book Value | -1,798,917 | -2,020,906 | -2,411,485 | -2,706,258 | -2,543,274 |
Tangible Book Value Per Share | -571.06 | -629.44 | -762.96 | -861.94 | -806.28 |